Acalabrutinib 100mg Capsules

Acalabrutinib 100mg is a targeted treatment for B-cell blood cancers, including chronic lymphocytic leukaemia and small lymphocytic lymphoma. It is also used in specific mantle-cell lymphoma regimens.
Take the capsules at roughly 12-hour intervals, with or without food, swallowing them whole. If an antacid is used, separate it by at least two hours; take acalabrutinib at least two hours before an H2 blocker. Proton-pump inhibitors are avoided with this capsule formulation.
Acalabrutinib blocks Bruton's tyrosine kinase within B cells. This interrupts signals supporting the growth, survival and movement of susceptible malignant B cells.
Headache, diarrhoea, fatigue, bruising and reduced blood counts can occur. Serious risks include bleeding, infections and heart-rhythm disturbances. Black stools, persistent fever, marked palpitations or new breathlessness needs prompt assessment.
Blood counts, infection history and hepatitis B status are assessed during treatment. Anticoagulants, antiplatelet medicines and CYP3A-interacting drugs can increase risk. Planned procedures need a bleeding-risk interruption plan. Skin protection and surveillance are relevant because secondary skin cancers can occur.
Can control abnormal B-cell growth and reduce disease-related symptoms in responsive blood cancers. Blood counts and lymph-node or spleen measurements help show how treatment is working.
Not automatically. Capsule absorption is sensitive to stomach acidity, while newer tablet formulations have different acid-reducer compatibility. The formulation matters even at the same 100mg strength.
BTK inhibition can impair platelet function as well as affect platelet counts. Dental work, biopsies and surgery may require a temporary interruption to reduce bleeding.
Skip the missed dose and take the next dose at the regular time. Do not take extra capsules to make up for it.
Yes. Atrial fibrillation or flutter can occur. Persistent palpitations, faintness, chest discomfort or breathlessness should be assessed promptly rather than attributed only to anxiety.
BTK: Bruton's tyrosine kinase, a B-cell signalling enzyme. B cell: immune cell from which certain blood cancers arise. CLL: chronic lymphocytic leukaemia. H2 blocker: medicine reducing stomach acid. Platelet function: ability of platelets to help stop bleeding.; AR: Acalabrutinib 100mg كبسولات; FR: Acalabrutinib 100mg gélules; PT: Acalabrutinib 100mg cápsulas; ES: Acalabrutinib 100mg cápsulas; RU: Acalabrutinib 100mg капсулы; ID: Acalabrutinib 100mg kapsul; VI: Acalabrutinib 100mg viên nang; MS: Acalabrutinib 100mg kapsul; TL: Acalabrutinib 100mg kapsula; ZH-SG: Acalabrutinib 100mg 胶囊
International B2B Enquiry
Send a structured B2B enquiry for Acalabrutinib 100mg Capsules under Oncology Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Acalabrutinib 100mg Capsules